Evidence map›Paper›PMID 35186496›Full record

ArticlePeerJ2022

Antiviral drug discovery by targeting the SARS-CoV-2 polyprotein processing by inhibition of the main protease.

Mahmoud Kandeel, Jinsoo Kim, Mahmoud Fayez, Yukio Kitade, Hyung-Joo Kwon

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 4 countries.

Mahmoud KandeelDepartment of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-hofuf, Al-ahsa, Saudi Arabia.
Jinsoo KimDepartment of Microbiology, College of Medicine, Hallym University, Chuncheon, South Korea.
Mahmoud FayezAl-Ahsa Veterinary Diagnostic Laboratory, Ministry of Agriculture, Al-Ahsa, Saudi Arabia.
Yukio KitadeDepartment of Applied Chemistry, Faculty of Engineering, Aichi Institute of Technology, Toyota, Japan.
Hyung-Joo KwonDepartment of Microbiology, College of Medicine, Hallym University, Chuncheon, South Korea.
Hallym University · KRAichi Institute of Technology · JPKafrelsheikh University · EGVeterinary Serum and Vaccine Research Institute · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spread of SARS-CoV-2, the causative agent for COVID-19, has led to a global and deadly pandemic. To date, few drugs have been approved for treating SARS-CoV-2 infections. In this study, a structure-based approach was adopted using the SARS-CoV-2 main protease (M

Indexed as

Antiviral AgentsCOVID-19Atazanavir SulfateHumansMolecular Docking SimulationPeptide HydrolasesPolyproteinsProtease InhibitorsSARS-CoV-2Antiviral AgentsAtazanavir SulfatePeptide HydrolasesPolyproteinsProtease InhibitorsCOVID-19Drug discoveryMain proteaseMolecular modelingSARS-CoV-2

Identifiers

PMID35186496
PMCPMC8833224
OpenAlexW4210872777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.